TAVR: If Not Transfemoral, We Should Consider Transcaval Access

Transcatheter aortic valve replacement (TAVR) through transfemoral access has already proven its great benefits, but this access cannot be used in certain patients, and alternative accesses need to be considered for such cases. One of the most commonly used accesses is the transaxillary or transubclavian access (AX), which, however, is associated with more complications (especially<a href="https://solaci.org/en/2022/06/01/tavr-if-not-transfemoral-we-should-consider-transcaval-access/" title="Read more" >...</a>

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | Should Revascularization Be Performed Before TAVR in Patients with Stable Coronary Disease?

Currently, the American and European guidelines recommend coronary angioplasty in patients with severe aortic stenosis with lesions >70% (Class IIa) who will undergo transcatheter aortic valve replacement (TAVR). However, the benefit of performing a revascularization in these patients is still uncertain. This prospective multicenter study included 2025 patients divided into two groups: complete revascularization (N = 1310)<a href="https://solaci.org/en/2022/05/24/europcr-2022-should-revascularization-be-performed-before-tavr-in-patients-with-stable-coronary-disease/" title="Read more" >...</a>

ACC 2022 | ADAPT-TAVR: Endoxaban Is Not Superior to DAPT After TAVR

DAPT-TAVR is a randomized trial that tested endoxaban in patients with no indication for anticoagulation who underwent successful transcatheter aortic valve replacement (TAVR) for symptomatic severe aortic stenosis. This study included 229 patients whose mean age was 80 years; 42% of them were male. Patients were randomized to either endoxaban 60 mg or 30 mg every 24 h or<a href="https://solaci.org/en/2022/04/13/acc-2022-adapt-tavr-endoxaban-is-not-superior-to-dapt-after-tavr/" title="Read more" >...</a>

estos son los artículos más leídos sobre tavi

Same-Day Discharger After TAVR: Are We There Yet?

Same-day discharge (SDD) has been shown to be effective in angioplasties and some peripheral procedures, but the pandemic—because of the burden it caused on the healthcare system—has forced the optimization of hospitalization times for other pathologies and procedures. This strategy is yet to be tested in transcatheter aortic valve replacement (TAVR) due to the possible<a href="https://solaci.org/en/2022/04/01/same-day-discharger-after-tavr-are-we-there-yet/" title="Read more" >...</a>

Last Articles in TAVR in solaci.org

We share the latest works in TAVI published on our website. Last Articles in TAVR in solaci.org 01- HYDRA CE | New Models for TAVR Development The Hydra CE has shown favorable one year efficacy for the new transcatheter aortic valve model, with large effective orifice and low transvalvular gradient associated to an acceptable complications rate.  With this study,<a href="https://solaci.org/en/2022/02/14/last-articles-in-tavr-in-solaci-org/" title="Read more" >...</a>

Minimizing One of Our Major Procedures to a Minimum

In some cases, full atrioventricular (AV) block occurs beyond two days after transcatheter aortic valve replacement (TAVR). This highlights the usefulness of extending monitoring after discharge, particularly in patients who tolerated the procedure well, but meet high-risk criteria. We have made great progress regarding conduction disorders in TAVR, especially after the publication of the consensus<a href="https://solaci.org/en/2022/01/13/minimizing-one-of-our-major-procedures-to-a-minimum/" title="Read more" >...</a>

The Most Relevant Articles of 2021 in Pharmacology

This last year, new data in pharmacology gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence. In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The Most Relevant<a href="https://solaci.org/en/2022/01/10/the-most-relevant-articles-of-2021-in-pharmacology/" title="Read more" >...</a>

The Most Relevant of 2021 In Structural Heart Disease

This last year, new data in structural heart disease gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence.  In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The<a href="https://solaci.org/en/2022/01/05/the-most-relevant-of-2021-in-structural-heart-disease/" title="Read more" >...</a>

Lo Más Leído de 2021 - Cardiopatia estructural

The Most Read Articles of 2021: Structural Heart Disease

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, peripheral vascular disease. Follow us to keep up to date. The Most Read Articles of 2021: Structural Heart Disease 01- Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis Recent<a href="https://solaci.org/en/2021/12/17/the-most-read-articles-of-2021-structural-heart-disease/" title="Read more" >...</a>

The most read scientific articles of november

November’s Most Read Studies in Interventional Cardiology in solaci.org

01- Management of Abdominal Aortic Aneurysms in 2021 Abdominal aortic aneurysms (AAA) are those of >3 cm aortic diameter.  They run the risk of rupture and ensuing death by bleeding. In consequence, they are treated to repair the aneurysm before it ruptures.  Read more HERE 02- Ten Commandments for 2021 Guidelines on Valvular Heart Disease Since<a href="https://solaci.org/en/2021/12/06/novembers-most-read-studies-in-interventional-cardiology-in-solaci-org/" title="Read more" >...</a>